3M’s Dividend Is Growing Again. Can PFAS Derail It?
With personal-injury claims still unresolved and the Solventum stake swinging reported earnings, income investors need to look past the headline number today.
SoftBank Wants to Own the Guards It Plans to Replace With Robots
Masayoshi Son’s reported $18 billion bid for Allied Universal is less a security play than a blueprint for automating America’s largest human workforce.
Jakarta’s $5.6 Billion Problem Is Bigger Than Jakarta
An MSCI governance shock shows how thin liquidity can break.
The Russell 2000 Is in Correction. The Dow’s Gain Hides Why.
Three indexes moved three directions last week. The loudest rate signal came from the one that fell hardest.
SAP Is the One AI Software Stock That Held Up. Wednesday Decides If It Deserves To.
SAP reports Q3 results on October 21. Watch cloud backlog.
CCC Got $7.75 a Share. Which Vertical Software Stock Is Next?
The GTCR-Elliott buyout paid a 44% premium for CCC. The opportunity is spotting what still trades publicly with a similar profile.
The Chip Trade Is Unwinding. Here Is Where It Stops.
Eight straight losses, a 21% VIX surge, and software joining the rout tell a specific story about which crowded positions still have room to fall.
Anthropic’s IPO May Be Weeks Away. An FTC Subpoena Raises the Stakes.
The FTC’s consumer-protection probe lands as Anthropic targets a $2 trillion IPO valuation, and confidentiality does not shield investors from regulatory risk.
Chinese Labs Are Writing the Next Decade of Drug Discovery. Who Keeps the Money?
A $139 billion year of out-licensing shifts the question from who discovers drugs to who captures the economics.
The KOSPI Fell Twice as Hard as the Nikkei. That Gap Is the Story.
Seoul’s circuit breakers and Tokyo’s Topix divergence show which stocks the world is selling, and why.